Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave Signs Partners to Distribute HPV Test in Spain, Portugal, and Italy

NEW YORK (GenomeWeb News) - Third Wave Technologies said today that Inverness Medical Iberica, a Spanish affiliate of Inverness Medical Innovations, will distribute its human papillomavirus screening test in Spain and Portugal.
 
Third Wave also said it has signed agreements with four “well-known regional distributors” to distribute its HPV product in Italy, though it did not identify those firms.
 
“We continue to negotiate with potential distributors for each of the other major markets in Europe and look forward to having them in place soon," said Kevin Conroy, president and CEO of Third Wave, in a statement. 
 
Third Wave’s HPV test gained European CE Marking certification in December.
 
The company’s test detects the presence of 14 high-risk types of HPV, the virus that causes nearly all cervical cancers.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.